| Company Name: |
Tianjin Kailiqi Biotechnology Co., Ltd.
|
| Tel: |
15076683720 |
| Email: |
klq@cw-bio.com |
| Products Intro: |
Product Name:N6F11
CAS:851398-76-0
Purity:大于98% Package:1g,5g,10g,25g根据客户需要分装 Remarks:Not For Human Use, Lab Use Only.
|
2-(chloromethyl)-6-(4-chlorophenyl)-3H,4H-thieno[3,2-d]pyrimidin-4-one manufacturers
- N6F11
-
- $195.00 / 1mg
-
2025-05-12
- CAS:851398-76-0
- Min. Order:
- Purity: 99.76%
- Supply Ability: 10g
|
| | 2-(chloromethyl)-6-(4-chlorophenyl)-3H,4H-thieno[3,2-d]pyrimidin-4-one Basic information |
| | 2-(chloromethyl)-6-(4-chlorophenyl)-3H,4H-thieno[3,2-d]pyrimidin-4-one Chemical Properties |
| form | Solid | | color | Off-white to light yellow |
| | 2-(chloromethyl)-6-(4-chlorophenyl)-3H,4H-thieno[3,2-d]pyrimidin-4-one Usage And Synthesis |
| Uses | N6F11 is a selective ferroptosis inducer, and can selectively induce ferroptosis by targeting TRIM25-mediated GPX4 degradation in cancer cells while sparing immune cells. N6F11 initiates HMGB1-dependent antitumor immunity mediated by CD8+ T cells[1][2][3][4]. | | References | [1] Li J, et al. Tumor-specific GPX4 degradation enhances ferroptosis-initiated antitumor immune response in mouse models of pancreatic cancer. Sci Transl Med. 2023;15(720):eadg3049. DOI:10.1126/scitranslmed.adg3049
[2] Liu J, et al. Cell type-specific induction of ferroptosis to boost antitumor immunity. Oncoimmunology. 2023 Nov 20;12(1):2282252. DOI:10.1080/2162402X.2023.2282252
[3] Shi TM, et al. Ferroptosis-Based Therapeutic Strategies toward Precision Medicine for Cancer. J Med Chem. 2024 Feb 22;67(4):2238-2263. DOI:10.1021/acs.jmedchem.3c01749
[4] Liu J, et al. Adverse effects of ferroptotic therapy: mechanisms and management. Trends Cancer. 2024 May;10(5):417-429. DOI:10.1016/j.trecan.2024.01.002 |
| | 2-(chloromethyl)-6-(4-chlorophenyl)-3H,4H-thieno[3,2-d]pyrimidin-4-one Preparation Products And Raw materials |
|